This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
novel coronavirus | 1251 |
coronavirus disease | 846 |
acute respiratory | 820 |
respiratory syndrome | 672 |
severe acute | 522 |
en el | 371 |
syndrome coronavirus | 370 |
clinical characteristics | 323 |
pacientes con | 299 |
severe covid | 290 |
respiratory distress | 264 |
en pacientes | 241 |
critically ill | 239 |
public health | 234 |
distress syndrome | 230 |
los pacientes | 223 |
se recomienda | 222 |
middle east | 203 |
east respiratory | 191 |
systematic review | 190 |
world health | 188 |
coronavirus pneumonia | 186 |
mental health | 186 |
con covid | 186 |
intensive care | 180 |
ill patients | 179 |
patients infected | 178 |
health organization | 177 |
health care | 174 |
confirmed cases | 174 |
hospitalized patients | 173 |
cancer patients | 165 |
convalescent plasma | 164 |
united states | 161 |
clinical features | 160 |
lopinavir ritonavir | 159 |
clinical trials | 155 |
risk factors | 155 |
chest ct | 154 |
respiratory tract | 151 |
nucleic acid | 151 |
coronavirus infection | 145 |
en los | 144 |
respiratory failure | 143 |
cytokine storm | 143 |
cohort study | 141 |
new coronavirus | 141 |
viral load | 139 |
clinical trial | 139 |
incubation period | 137 |
mechanical ventilation | 135 |
infected patients | 134 |
viral rna | 128 |
el uso | 128 |
fatality rate | 127 |
converting enzyme | 118 |
spike protein | 118 |
immune response | 118 |
del paciente | 116 |
pregnant women | 116 |
gastrointestinal symptoms | 116 |
clinical course | 114 |
disease control | 108 |
medical staff | 107 |
human transmission | 106 |
infected pneumonia | 102 |
sars coronavirus | 102 |
para el | 101 |
infectious diseases | 98 |
care unit | 98 |
social distancing | 97 |
el paciente | 97 |
symptom onset | 95 |
por covid | 95 |
lung injury | 94 |
severe cases | 93 |
con el | 93 |
healthcare workers | 91 |
case series | 90 |
confirmed covid | 88 |
cord uid | 88 |
doc id | 88 |
infectious disease | 87 |
mortality rate | 87 |
hong kong | 85 |
severe disease | 85 |
heart failure | 84 |
immune responses | 77 |
sin embargo | 77 |
descriptive study | 77 |
con sospecha | 76 |
hubei province | 76 |
asymptomatic patients | 75 |
transmission dynamics | 74 |
among patients | 73 |
first case | 73 |
disease severity | 73 |
protective equipment | 73 |
observational study | 73 |
immune system | 73 |
increased risk | 72 |
cov infection | 72 |
paciente con | 71 |
con un | 71 |
coronavirus infections | 70 |
retrospective cohort | 70 |
cardiovascular disease | 70 |
respiratory disease | 69 |
controlled trial | 68 |
human coronavirus | 67 |
clinical manifestations | 67 |
personal protective | 67 |
viral infection | 67 |
upper respiratory | 66 |
care workers | 66 |
antiviral drugs | 66 |
case fatality | 65 |
con una | 65 |
antiviral activity | 65 |
sars cov | 65 |
clinical outcomes | 64 |
rna polymerase | 64 |
lung cancer | 64 |
nervous system | 64 |
en un | 63 |
higher risk | 63 |
retrospective study | 63 |
host cell | 63 |
seafood market | 62 |
global health | 62 |
viral infections | 62 |
se ha | 62 |
vertical transmission | 62 |
national health | 61 |
case report | 61 |
corona virus | 61 |
por el | 61 |
another study | 61 |
traditional chinese | 60 |
ebola virus | 60 |
randomized controlled | 60 |
respiratory symptoms | 59 |
randomized clinical | 59 |
glass opacities | 59 |
spike glycoprotein | 59 |
receptor binding | 58 |
high risk | 58 |
ground glass | 58 |
ace receptor | 58 |
epithelial cells | 57 |
study clinical | 56 |
myocardial injury | 56 |
el manejo | 56 |
por sars | 56 |
respiratory infections | 56 |
viral shedding | 55 |
close contact | 55 |
control measures | 54 |
se debe | 54 |
new york | 54 |
cardiac injury | 54 |
chinese medicine | 53 |
host cells | 53 |
infected individuals | 53 |
viral replication | 53 |
critical care | 53 |
un estudio | 53 |
pacientes en | 52 |
el riesgo | 52 |
human coronaviruses | 52 |
case reports | 52 |
early stage | 52 |
coronavirus outbreak | 51 |
rna viruses | 51 |
reactive protein | 51 |
recent study | 51 |
may also | 51 |
epidemiological characteristics | 51 |
clinical symptoms | 51 |
en las | 50 |
person transmission | 50 |
reproduction number | 50 |
inflammatory response | 50 |
tested positive | 50 |
lower respiratory | 50 |
health commission | 50 |
china clinical | 50 |
clinical presentation | 49 |
situation report | 49 |
kidney injury | 48 |
se puede | 48 |
infection control | 48 |
bat origin | 48 |
binding domain | 48 |
family cluster | 48 |
pneumonia outbreak | 47 |
chain reaction | 47 |
health emergency | 47 |
virus disease | 46 |
south korea | 46 |
chinese center | 46 |
antibody responses | 46 |
close contacts | 45 |
cuidados intensivos | 45 |
icu patients | 45 |
por lo | 45 |
spectrum antiviral | 44 |
respiratory infection | 44 |
pao fio | 44 |
reproductive number | 44 |
ct scans | 43 |
el grupo | 43 |
poor prognosis | 43 |
severe pneumonia | 43 |
common symptoms | 43 |
previous studies | 43 |
intermediate host | 42 |
patients admitted | 42 |
adverse events | 42 |
amino acid | 42 |
influenza virus | 42 |
el tratamiento | 42 |
en una | 42 |
clinical studies | 42 |
early transmission | 42 |
patients receiving | 41 |
polymerase chain | 41 |
health services | 41 |
reverse transcription | 41 |
oxygen therapy | 41 |
virus infection | 41 |
early stages | 41 |
monoclonal antibody | 40 |
ncov infection | 40 |
early phase | 40 |
artificial intelligence | 40 |
ace receptors | 40 |
acute kidney | 40 |
membrane oxygenation | 40 |
ct findings | 40 |
computed tomography | 40 |
familial cluster | 40 |
antiviral drug | 40 |
sars outbreak | 39 |
clinical findings | 39 |
suspected covid | 39 |
en cuenta | 39 |
plasma convaleciente | 39 |
myocardial infarction | 39 |
viral loads | 39 |
respiratory droplets | 39 |
extracorporeal membrane | 39 |
factors associated | 39 |
sore throat | 39 |
contact tracing | 38 |
organ failure | 38 |
study reported | 38 |
made available | 38 |
structural proteins | 38 |
even though | 38 |
older adults | 37 |
saudi arabia | 37 |
face mask | 37 |
central nervous | 37 |
international license | 37 |
severe respiratory | 37 |
prone positioning | 37 |
important lessons | 37 |
dependent rna | 37 |
glass opacity | 37 |
treat covid | 36 |
patients without | 36 |
widely used | 36 |
asymptomatic carriers | 36 |
general population | 36 |
se han | 36 |
plasma therapy | 36 |
copyright holder | 36 |
adult inpatients | 36 |
wuhan city | 36 |
patients hospitalized | 36 |
septic shock | 36 |
mg kg | 36 |
protease inhibitor | 36 |
viral clearance | 35 |
wild animals | 35 |
family members | 35 |
pulmonary embolism | 35 |
hand hygiene | 35 |
chloroquine phosphate | 35 |
con los | 35 |
vaccine development | 35 |
asymptomatic cases | 35 |
sars patients | 35 |
patients may | 35 |
coronavirus sars | 35 |
new cases | 34 |
inflammatory cytokines | 34 |
time rt | 34 |
patients treated | 34 |
age groups | 34 |
study showed | 34 |
many countries | 34 |
neutralizing antibodies | 34 |
multiple organ | 34 |
viral genome | 34 |
animal models | 34 |
oral transmission | 34 |
pit latrines | 34 |
pediatric patients | 34 |
related coronavirus | 34 |
granted medrxiv | 33 |
author funder | 33 |
common cold | 33 |
clinical data | 33 |
years old | 33 |
interim guidance | 33 |
acute lung | 33 |
cell entry | 33 |
important role | 33 |
viral entry | 33 |
neurological manifestations | 33 |
one study | 32 |
isothermal amplification | 32 |
severe coronavirus | 32 |
en su | 32 |
respiratory illness | 32 |
preventive measures | 32 |
effectively inhibit | 32 |
todos los | 32 |
acid detection | 32 |
cytokine release | 32 |
side effects | 32 |
associated pneumonia | 32 |
innate immune | 32 |
coronavirus indicating | 32 |
genome sequence | 32 |
clinical practice | 32 |
clinical signs | 32 |
viral pneumonia | 32 |
infected people | 31 |
coronavirus spike | 31 |
nasopharyngeal swab | 31 |
su uso | 31 |
test results | 31 |
disease outbreaks | 31 |
risk factor | 31 |
suspected cases | 31 |
herd immunity | 31 |
basic reproduction | 31 |
outbreak associated | 31 |
recently emerged | 31 |
adult patients | 31 |
emerged novel | 31 |
bat sars | 31 |
cell membrane | 31 |
probable bat | 31 |
age group | 31 |
respiratory specimens | 31 |
treatment options | 31 |
treating covid | 31 |
diabetes mellitus | 30 |
infected person | 30 |
asymptomatic infection | 30 |
chloroquine effectively | 30 |
organ dysfunction | 30 |
debe ser | 30 |
pneumonia associated | 30 |
orf ab | 30 |
los estudios | 30 |
human ace | 30 |
compassionate use | 30 |
del virus | 30 |
median time | 30 |
lactate dehydrogenase | 30 |
potential therapeutic | 30 |
invasive mechanical | 30 |
en uci | 30 |
underlying diseases | 29 |
modelling study | 29 |
reported cases | 29 |
stem cells | 29 |
respiratory viruses | 29 |
es un | 29 |
early diagnosis | 29 |
available online | 29 |
control group | 29 |
respiratory diseases | 29 |
asymptomatic carrier | 29 |
nucleic acids | 29 |
como el | 29 |
large number | 29 |
asymptomatic infections | 29 |
dry cough | 29 |
release syndrome | 28 |
ace expression | 28 |
median age | 28 |
el cual | 28 |
health authorities | 28 |
adults hospitalized | 28 |
con sdra | 28 |
several studies | 28 |
viral nucleic | 28 |
intermediate hosts | 28 |
acute cardiac | 28 |
left ventricular | 28 |
kidney disease | 28 |
huanan seafood | 28 |
income countries | 28 |
first cases | 27 |
stranded rna | 27 |
authors declare | 27 |
serine protease | 27 |
hospital admission | 27 |
interferon beta | 27 |
puede ser | 27 |
international committee | 27 |
noninvasive ventilation | 27 |
also reported | 27 |
animal species | 27 |
membrane fusion | 27 |
respiratory support | 27 |
severe patients | 27 |
infection prevention | 27 |
emerging coronaviruses | 27 |
blood pressure | 27 |
rheumatoid arthritis | 27 |
indicating person | 27 |
protease inhibitors | 27 |
first reported | 26 |
nasal cannula | 26 |
clinical management | 26 |
laboratory findings | 26 |
el momento | 26 |
mortality rates | 26 |
clinical cases | 26 |
ct imaging | 26 |
bronchoalveolar lavage | 26 |
en contra | 26 |
neurologic manifestations | 26 |
el inicio | 26 |
en este | 26 |
abdominal pain | 26 |
symptomatic cases | 26 |
imaging features | 26 |
supportive care | 26 |
disease prevention | 26 |
stem cell | 26 |
vitro activity | 26 |
asymptomatic contact | 25 |
es importante | 25 |
severe infection | 25 |
los cuales | 25 |
operating room | 25 |
mesenchymal stem | 25 |
global pandemic | 25 |
angiotensin system | 25 |
infected persons | 25 |
cuidado intensivo | 25 |
therapeutic options | 25 |
york city | 25 |
sobre el | 25 |
deep learning | 25 |
serological tests | 25 |
human respiratory | 25 |
phylogenetic analysis | 25 |
los casos | 25 |
expert opinion | 25 |
entre los | 25 |
clinical specimens | 25 |
current evidence | 25 |
el tiempo | 25 |
total number | 25 |
face masks | 25 |
million people | 25 |
corticosteroid treatment | 25 |
vitro antiviral | 25 |
rapid detection | 25 |
transmission potential | 25 |
cancer care | 25 |
bat coronavirus | 24 |
disease caused | 24 |
pcr test | 24 |
ct scan | 24 |
imaging findings | 24 |
pathological findings | 24 |
respiratory syncytial | 24 |
sample size | 24 |
observational cohort | 24 |
en caso | 24 |
acid testing | 24 |
flow nasal | 24 |
teniendo en | 24 |
sars epidemic | 24 |
syncytial virus | 24 |
en china | 24 |
syndrome associated | 24 |
igg antibodies | 24 |
el personal | 24 |
health system | 24 |
laboratory testing | 24 |
patients showed | 24 |
creatine kinase | 24 |
health workers | 24 |
creative commons | 24 |
twice daily | 24 |
nucleocapsid protein | 24 |
disease progression | 24 |
per day | 24 |
disease outbreak | 23 |
specific antibodies | 23 |
retrospective review | 23 |
es el | 23 |
closely related | 23 |
clinical evidence | 23 |
serial interval | 23 |
may cause | 23 |
ill covid | 23 |
si el | 23 |
care units | 23 |
venous thromboembolism | 23 |
much higher | 23 |
cruise ship | 23 |
mechanically ventilated | 23 |
international concern | 23 |
ncov pneumonia | 23 |
clinical study | 23 |
tract infections | 23 |
severe ards | 23 |
transmission rate | 23 |
diamond princess | 23 |
within days | 23 |
direct contact | 23 |
travel history | 23 |
hospitalized covid | 22 |
clinical improvement | 22 |
combination therapy | 22 |
para evitar | 22 |
icu admission | 22 |
therapeutic efficacy | 22 |
chest pain | 22 |
kawasaki disease | 22 |
stool samples | 22 |
estos pacientes | 22 |
virus origins | 22 |
es una | 22 |
antiviral treatment | 22 |
rapid spread | 22 |
functional receptor | 22 |
monoclonal antibodies | 22 |
neonates born | 22 |
united kingdom | 22 |
higher mortality | 22 |
also found | 22 |
elevated levels | 22 |
del estado | 22 |
among covid | 22 |
molecular modeling | 22 |
antibody response | 22 |
differential diagnosis | 22 |
seasonal influenza | 22 |
high mortality | 22 |
medical records | 22 |
coronavirus pandemic | 22 |
critical covid | 22 |
elderly patients | 22 |
effective treatment | 22 |
consentimiento informado | 22 |
type i | 21 |
critical cases | 21 |
para pacientes | 21 |
accessory proteins | 21 |
receptor ace | 21 |
different types | 21 |
pcr testing | 21 |
para los | 21 |
una serie | 21 |
secondary infection | 21 |
wuhan clinical | 21 |
coronavirus associated | 21 |
healthcare personnel | 21 |
emergency department | 21 |
young adults | 21 |
cual se | 21 |
pneumonia cases | 21 |
disease patients | 21 |
study group | 21 |
coronavirus diseases | 21 |
heart disease | 21 |
mediated isothermal | 21 |
symptomatic patients | 21 |
falla respiratoria | 21 |
including sars | 21 |
health measures | 21 |
mainland china | 21 |
sepsis campaign | 21 |
recent studies | 21 |
surviving sepsis | 21 |
digestive symptoms | 21 |
controlled trials | 21 |
han sido | 21 |
available data | 21 |
inflammatory drugs | 21 |
civil society | 20 |
viral transmission | 20 |
disseminated intravascular | 20 |
unknown etiology | 20 |
study conducted | 20 |
human cells | 20 |
broad spectrum | 20 |
prone position | 20 |
mild cases | 20 |
radiological findings | 20 |
control strategies | 20 |
cardiovascular complications | 20 |
rna virus | 20 |
expert consensus | 20 |
cardiogenic shock | 20 |
significantly higher | 20 |
lo tanto | 20 |
cell culture | 20 |
novel virus | 20 |
infect humans | 20 |
pneumonia clinical | 20 |
multicenter study | 20 |
hospital stay | 20 |
negative results | 20 |
antiviral agents | 20 |
health systems | 20 |
outcomes among | 20 |
nine pregnant | 20 |
adverse effects | 20 |
intravascular coagulation | 20 |
comorbid conditions | 20 |
atypical pneumonia | 20 |
highly contagious | 20 |
mild symptoms | 20 |
tratamiento con | 20 |
respiratory viral | 20 |
blood cell | 20 |
consensus statement | 20 |
therapeutic agents | 20 |
hasta el | 20 |
clinical diagnosis | 20 |
white blood | 20 |
virus replication | 19 |
surface stability | 19 |
el estudio | 19 |
las recomendaciones | 19 |
antiviral therapy | 19 |
chinese government | 19 |
retrospective case | 19 |
lo cual | 19 |
health interventions | 19 |
national institute | 19 |
alto flujo | 19 |
older age | 19 |
weak recommendation | 19 |
community transmission | 19 |
wide range | 19 |
en cuanto | 19 |
patients reported | 19 |
chronic kidney | 19 |
time course | 19 |
one health | 19 |
acute myocardial | 19 |
nationwide analysis | 19 |
receptor blockers | 19 |
lymphocyte count | 19 |
clinical microbiology | 19 |
label non | 19 |
intrauterine vertical | 19 |
contar con | 19 |
disease course | 19 |
bat coronaviruses | 19 |
confirmed case | 19 |
within weeks | 19 |
emerging infectious | 19 |
day mortality | 19 |
angiotensin converting | 19 |
en covid | 19 |
potential role | 19 |
early detection | 19 |
two patients | 18 |
care systems | 18 |
asymptomatic transmission | 18 |
rna genome | 18 |
positive rate | 18 |
lessons learned | 18 |
los efectos | 18 |
receptor recognition | 18 |
associated coronavirus | 18 |
neutralizing antibody | 18 |
involving patients | 18 |
unknown origin | 18 |
amino acids | 18 |
del covid | 18 |
healthcare professionals | 18 |
effective vaccine | 18 |
throat swab | 18 |
novel corona | 18 |
con enfermedad | 18 |
will help | 18 |
durante el | 18 |
intravenous immunoglobulin | 18 |
liver injury | 18 |
current pandemic | 18 |
tratados con | 18 |
ng ml | 18 |
laboratory tests | 18 |
fecal nucleic | 18 |
genomic characterisation | 18 |
protease tmprss | 18 |
forma rutinaria | 18 |
genome sequences | 18 |
pathogenic coronaviruses | 18 |
lung changes | 18 |
ischemic stroke | 18 |
nitric oxide | 18 |
carrier transmission | 18 |
se sugiere | 18 |
desde el | 18 |
cuando se | 18 |
fatality rates | 18 |
recomienda en | 18 |
severe illness | 18 |
oxygen saturation | 18 |
gastrointestinal manifestations | 18 |
las cuales | 18 |
pulmonary disease | 18 |
like sars | 18 |
acuerdo con | 18 |
coronavirus epidemic | 18 |
main protease | 18 |
las condiciones | 17 |
genome structure | 17 |
recently published | 17 |
cardiovascular system | 17 |
spike proteins | 17 |
alveolar damage | 17 |
analysis based | 17 |
decreased mortality | 17 |
breast milk | 17 |
host immune | 17 |
una estrategia | 17 |
malayan pangolins | 17 |
symptoms onset | 17 |
deceased patients | 17 |
inhibit sars | 17 |
crucial role | 17 |
among medical | 17 |
pilot study | 17 |
infection rate | 17 |
transplant recipients | 17 |
machine learning | 17 |
critical patients | 17 |
containment measures | 17 |
cell lines | 17 |
positive patients | 17 |
care medicine | 17 |
psychological impact | 17 |
chest imaging | 17 |
sectional study | 17 |
literature review | 17 |
ct features | 17 |
coronavirus hku | 17 |
human monoclonal | 17 |
gas exchange | 17 |
solid tumours | 17 |
least one | 17 |
new virus | 17 |
medical workers | 17 |
acute pulmonary | 17 |
cerebrovascular disease | 17 |
citation networks | 17 |
ill adults | 17 |
seafood wholesale | 17 |
confidence interval | 17 |
inhibiting sars | 17 |
viral envelope | 17 |
septal thickening | 17 |
en estado | 17 |
second wave | 17 |
china coronavirus | 17 |
epidemiologic features | 17 |
associated acute | 17 |
north america | 17 |
high viral | 17 |
wholesale market | 17 |
spread rapidly | 17 |
haematological malignancies | 17 |
moderate covid | 17 |
coronaviridae family | 17 |
days later | 17 |
mers coronavirus | 17 |
social media | 17 |
coronary artery | 16 |
abnormal coagulation | 16 |
asymptomatic sars | 16 |
drug repurposing | 16 |
th day | 16 |
pandemic influenza | 16 |
virus spread | 16 |
comparado con | 16 |
version posted | 16 |
type ii | 16 |
positive cases | 16 |
carga viral | 16 |
una vez | 16 |
coagulation parameters | 16 |
los servicios | 16 |
confirmed patients | 16 |
treatment guidelines | 16 |
basic reproductive | 16 |
studies showed | 16 |
china joint | 16 |
ct images | 16 |
interlobular septal | 16 |
ha sido | 16 |
physical distancing | 16 |
del tratamiento | 16 |
symptomatic rate | 16 |
novel sars | 16 |
cols en | 16 |
posted march | 16 |
corticosteroid therapy | 16 |
severe sars | 16 |
angiotensin ii | 16 |
new drugs | 16 |
peripheral blood | 16 |
drug administration | 16 |
old male | 16 |
days prior | 16 |
pueden ser | 16 |
human body | 16 |
care system | 16 |
immune cells | 16 |
sputum production | 16 |
el sars | 16 |
media briefing | 16 |
higher levels | 16 |
viral proteins | 16 |
prospective cohort | 16 |
viral diseases | 16 |
cell responses | 16 |
lung involvement | 16 |
critical illness | 16 |
del uso | 16 |
respiratory pathogens | 16 |
inflammatory syndrome | 16 |
para su | 16 |
high level | 16 |
em structure | 16 |
envelope protein | 16 |
patients received | 16 |
acute coronary | 16 |
may lead | 16 |
patients dying | 16 |
cov infections | 16 |
emergency use | 16 |
medrxiv preprint | 16 |
positive results | 16 |
medical care | 16 |
compromiso pulmonar | 16 |
march th | 16 |
los trabajadores | 16 |
como una | 16 |
psychological interventions | 16 |
recovered patients | 16 |
virus entry | 16 |
bacterial infection | 16 |
genomic characterization | 16 |
apparent efficacy | 16 |
trial version | 16 |
commonly used | 16 |
manejo del | 16 |
population density | 16 |
presumed asymptomatic | 16 |
clinical analysis | 16 |
innate immunity | 16 |
medical treatment | 16 |
epidemiological features | 16 |
fecal viral | 16 |
body temperature | 16 |
cell receptor | 16 |
china reported | 16 |
nonstructural proteins | 15 |
fulminant myocarditis | 15 |
replacement therapy | 15 |
risk covid | 15 |
drug discovery | 15 |
standard care | 15 |
ncov infected | 15 |
los niveles | 15 |
serological investigation | 15 |
emerging coronavirus | 15 |
one patient | 15 |
guangdong province | 15 |
may result | 15 |
disease transmission | 15 |
first identified | 15 |
data available | 15 |
zoonotic coronaviruses | 15 |
new year | 15 |
pregnant patients | 15 |
patients developed | 15 |
ncov outbreak | 15 |
emerging viruses | 15 |
los recursos | 15 |
global spread | 15 |
pandemia covid | 15 |
high sensitivity | 15 |
dificultad respiratoria | 15 |
mild moderate | 15 |
antiviral effects | 15 |
humoral response | 15 |
adaptive immune | 15 |
affected countries | 15 |
las personas | 15 |
among children | 15 |
favor fundamento | 15 |
adverse outcomes | 15 |
severely ill | 15 |
confirmed sars | 15 |
clinical samples | 15 |
rhesus macaques | 15 |
increased mortality | 15 |
crispr cas | 15 |
acquired pneumonia | 15 |
el estado | 15 |
qt interval | 15 |
pacientes covid | 15 |
gastrointestinal tract | 15 |
entre el | 15 |
coronavirus causing | 15 |
initial virological | 15 |
lung disease | 15 |
health concern | 15 |
remains unclear | 15 |
bei kindern | 15 |
coronavirus covid | 15 |
los primeros | 15 |
invasive ventilation | 15 |
pulmonary edema | 15 |
preliminary estimation | 15 |
clinical benefit | 15 |
logistic regression | 15 |
del personal | 15 |
complement system | 15 |
shown apparent | 15 |
many patients | 15 |
si se | 15 |
less likely | 15 |
human beings | 15 |
patients presented | 15 |
joint mission | 15 |
cases reported | 15 |
recomienda realizar | 15 |
avian influenza | 15 |
cellular receptor | 15 |
pacientes hospitalizados | 15 |
emitir una | 15 |
antibody titers | 15 |
alveolar macrophages | 15 |
severe symptoms | 15 |
potential treatment | 15 |
driven analysis | 15 |
healthcare systems | 15 |
las medidas | 15 |
nuevo coronavirus | 15 |
swab samples | 15 |
dimer levels | 15 |
therapeutic strategies | 15 |
influenza pandemic | 15 |
con las | 15 |
currently available | 14 |
human immunodeficiency | 14 |
throat swabs | 14 |
renal replacement | 14 |
medical history | 14 |
es necesario | 14 |
highly infectious | 14 |
neurological symptoms | 14 |
novel human | 14 |
less severe | 14 |
microbiology reviews | 14 |
mean incubation | 14 |
molecular targets | 14 |
las primeras | 14 |
laboratory diagnosis | 14 |
outside china | 14 |
results showed | 14 |
global public | 14 |
narrative review | 14 |
death rate | 14 |
thromboembolic events | 14 |
ongoing covid | 14 |
epidemiological data | 14 |
chinese herbal | 14 |
patients diagnosed | 14 |
ha demostrado | 14 |
presymptomatic transmission | 14 |
gold standard | 14 |
southern china | 14 |
cause severe | 14 |
ncov spike | 14 |
genetic recombination | 14 |
patients requiring | 14 |
sense rna | 14 |
mild disease | 14 |
care providers | 14 |
antiviral effect | 14 |
like protease | 14 |
term care | 14 |
princess cruise | 14 |
immune function | 14 |
early recognition | 14 |
alto riesgo | 14 |
endotracheal intubation | 14 |
virus rna | 14 |
por coronavirus | 14 |
urgently needed | 14 |
emerging novel | 14 |
bat cov | 14 |
diagnostic tests | 14 |
international spread | 14 |
outside wuhan | 14 |
may occur | 14 |
preliminary report | 14 |
alanine aminotransferase | 14 |
en paciente | 14 |
four patients | 14 |
species transmission | 14 |
study covid | 14 |
detection rate | 14 |
doubling time | 14 |
prothrombin time | 14 |
species barrier | 14 |
include fever | 14 |
chronic obstructive | 14 |
para evaluar | 14 |
washington state | 14 |
like symptoms | 14 |
control study | 14 |
system inhibitors | 14 |
studies reported | 14 |
study found | 14 |
jurisdictional claims | 14 |
patients aged | 14 |
clinically proven | 14 |
coronavirus isolated | 14 |
specific antiviral | 14 |
protective immunity | 14 |
targeted therapy | 14 |
con pacientes | 14 |
fluid responsiveness | 14 |
digestive tract | 14 |
asociado con | 14 |
del sistema | 14 |
evidence suggests | 14 |
may play | 14 |
worse outcomes | 14 |
cov virus | 14 |
antibody test | 14 |
human intestinal | 14 |
phase i | 14 |
entry depends | 14 |
management strategies | 14 |
chinese medicines | 14 |
lavage fluid | 14 |
magnetic resonance | 14 |
among close | 14 |
death toll | 14 |
remains neutral | 14 |
transmembrane serine | 14 |
distancing measures | 14 |
dipeptidyl peptidase | 14 |
aldosterone system | 14 |
proven protease | 14 |
infected medical | 14 |
genome sequencing | 14 |
relative infectiousness | 14 |
quarantine measures | 14 |
electron microscopy | 14 |
donde se | 14 |
respiratory system | 14 |
stool viral | 14 |
reverse transcriptase | 14 |
influenza vaccine | 14 |
el traslado | 14 |
deben ser | 14 |
also used | 14 |
immunodeficiency virus | 14 |
still unclear | 14 |
sars virus | 14 |
current outbreak | 13 |
may help | 13 |
disminuir el | 13 |
patients presenting | 13 |
hospitalizados con | 13 |
za zhi | 13 |
icu care | 13 |
virus infections | 13 |
environmental factors | 13 |
basado en | 13 |
macrophage activation | 13 |
relative humidity | 13 |
un protocolo | 13 |
zoonotic spillover | 13 |
surgical masks | 13 |
mg dl | 13 |
preliminary results | 13 |
relationship quality | 13 |
infectious bronchitis | 13 |
molecular weight | 13 |
highly expressed | 13 |
low molecular | 13 |
mayor riesgo | 13 |
like coronavirus | 13 |
human sars | 13 |
segment elevation | 13 |
genetic sequence | 13 |
serological assays | 13 |
retrospective studies | 13 |
increasing number | 13 |
institutional affiliations | 13 |
tener en | 13 |
response team | 13 |
viral spread | 13 |
mg twice | 13 |
clinical efficacy | 13 |
risk assessment | 13 |
nature remains | 13 |
also known | 13 |
obstructive pulmonary | 13 |
optimized dosing | 13 |
respiratory rate | 13 |
patients undergoing | 13 |
animal model | 13 |
experts suggest | 13 |
dosing design | 13 |
con respecto | 13 |
sex differences | 13 |
unclear whether | 13 |
like coronaviruses | 13 |
first confirmed | 13 |
transmission risk | 13 |
younger age | 13 |
will need | 13 |
symptoms included | 13 |
data suggest | 13 |
specific antibody | 13 |
infection among | 13 |
specific treatment | 13 |
molecular mechanisms | 13 |
two cases | 13 |
prefusion conformation | 13 |
asymptomatic individuals | 13 |
el objetivo | 13 |
center study | 13 |
artery disease | 13 |
pharmaceutical interventions | 13 |
renal failure | 13 |
study also | 13 |
cleavage site | 13 |
los criterios | 13 |
viral respiratory | 13 |
may increase | 13 |
life support | 13 |
journal pre | 13 |
analysis showed | 13 |
springer nature | 13 |
published maps | 13 |
umbilical cord | 13 |
camostat mesylate | 13 |
structural models | 13 |
positive rt | 13 |
emergency response | 13 |
based vaccine | 13 |
respiratory samples | 13 |
odds ratio | 13 |
igg antibody | 13 |
anticoagulant treatment | 13 |
male sex | 13 |
rural china | 13 |
note springer | 13 |
falla renal | 13 |
recent advances | 13 |
protective measures | 13 |
pneumonia caused | 13 |
clinical picture | 13 |
psychological distress | 13 |
structural studies | 13 |
tested negative | 13 |
diffuse alveolar | 13 |
published literature | 13 |
genetic material | 13 |
el consentimiento | 13 |
younger patients | 13 |
china novel | 13 |
limited data | 13 |
scientific community | 13 |
direct viral | 13 |
single center | 13 |
cuenta con | 13 |
wuhan coronavirus | 13 |
across countries | 13 |
aspartate aminotransferase | 13 |
inflammatory markers | 13 |
para sars | 13 |
natural reservoir | 13 |
las muestras | 13 |
ii clinical | 13 |
con hipoxemia | 13 |
cardiac troponin | 13 |
un mayor | 13 |
pregnant mothers | 13 |
mrna vaccine | 13 |
opening remarks | 13 |
lung recruitability | 13 |
health professionals | 13 |
pneumonia diagnosis | 13 |
open access | 13 |
animal host | 13 |
molecular docking | 13 |
driving pressure | 13 |
american society | 13 |
whole genome | 13 |
suspected case | 13 |
estancia en | 13 |
first covid | 13 |
generating procedures | 13 |
time reverse | 13 |
human infection | 13 |
se le | 13 |
south china | 12 |
olfactory dysfunction | 12 |
hypoxemic respiratory | 12 |
tracto respiratorio | 12 |
developmental state | 12 |
hospital discharge | 12 |
el contexto | 12 |
potent antiviral | 12 |
american college | 12 |
older patients | 12 |
long structural | 12 |
tissue distribution | 12 |
developing countries | 12 |
este estudio | 12 |
renal aguda | 12 |
viral particles | 12 |
named sars | 12 |
emerging viral | 12 |
severely affected | 12 |
significant difference | 12 |
shedding routes | 12 |
less toxic | 12 |
infants born | 12 |
thoracic society | 12 |
first time | 12 |
serum samples | 12 |
asymptomatic covid | 12 |
requiring hospitalization | 12 |
current understanding | 12 |
million confirmed | 12 |
grupo control | 12 |
immune checkpoint | 12 |
human covs | 12 |
epidemic situation | 12 |
diagnostic test | 12 |
air pollution | 12 |
ace inhibitors | 12 |
structural basis | 12 |
isolation wards | 12 |
evolutionary analysis | 12 |
new disease | 12 |
chest radiograph | 12 |
frecuencia respiratoria | 12 |
negative pressure | 12 |
diagnostic methods | 12 |
confirmed ncovid | 12 |
reported confirmed | 12 |
virus transmission | 12 |
treatment option | 12 |
acute renal | 12 |
healthcare settings | 12 |
airway epithelial | 12 |
novel coronaviruses | 12 |
enfermedad por | 12 |
european society | 12 |
health service | 12 |
higher rates | 12 |
commons licence | 12 |
deaths due | 12 |
induced lung | 12 |
pacientes recibieron | 12 |
los resultados | 12 |
sierra leone | 12 |
developed using | 12 |
pneumonia patients | 12 |
higher compared | 12 |
median incubation | 12 |
multiple shedding | 12 |
first patient | 12 |
infection caused | 12 |
therapeutic targets | 12 |
short period | 12 |
un paciente | 12 |
antiviral agent | 12 |
first step | 12 |
ii alveolar | 12 |
sequence identity | 12 |
en salud | 12 |
treat ncovid | 12 |
systemic arterial | 12 |
combination lopinavir | 12 |
cutaneous manifestations | 12 |
mg day | 12 |
dependent enhancement | 12 |
citation network | 12 |
transcription loop | 12 |
multisystem inflammatory | 12 |
bilateral ground | 12 |
patients suffering | 12 |
airway pressure | 12 |
se encuentra | 12 |
outbreak originating | 12 |
cell surface | 12 |
potent inhibitor | 12 |
first week | 12 |
mouse model | 12 |
existing comorbidities | 12 |
group vs | 12 |
rna detection | 12 |
takes place | 12 |
tract specimens | 12 |
school closures | 12 |
pleural effusion | 12 |
el rendimiento | 12 |
respiratory virus | 12 |
sequence alignment | 12 |
lung tissue | 12 |
death rates | 12 |
digestive system | 12 |
deaths per | 12 |
transmission route | 12 |
may need | 12 |
airborne transmission | 12 |
first day | 12 |
virological assessment | 12 |
equipment contamination | 12 |
scientific evidence | 12 |
health problems | 12 |
comprehensive review | 12 |
puede emitir | 12 |
chronic diseases | 12 |
uso del | 12 |
deep sedation | 12 |
zika virus | 12 |
severe outcomes | 12 |
preterm birth | 12 |
fever clinics | 12 |
surface environmental | 12 |
chest computed | 12 |
human airway | 12 |
target cells | 12 |
surgical procedures | 12 |
gastrointestinal infection | 12 |
lateral flow | 12 |
recomienda el | 12 |
coreldraw software | 11 |
como los | 11 |
higher viral | 11 |
johns hopkins | 11 |
infected cases | 11 |
cov epidemic | 11 |
con tcz | 11 |
less common | 11 |
los respiradores | 11 |
del tracto | 11 |
declared covid | 11 |
cardiac arrest | 11 |
publicly reported | 11 |
th july | 11 |
multiorgan failure | 11 |
binding affinity | 11 |
el punto | 11 |
health crisis | 11 |
thromboembolic disease | 11 |
requiring mechanical | 11 |
promising results | 11 |
clinical manifestation | 11 |
con mayor | 11 |
virus may | 11 |
china characteristics | 11 |
coronavirus replication | 11 |
tract infection | 11 |
chemotherapy within | 11 |
drug treatment | 11 |
data obtained | 11 |
mortality due | 11 |
weight heparin | 11 |
el fin | 11 |
china covid | 11 |
fecal samples | 11 |
hospital mortality | 11 |
corporation id | 11 |
one month | 11 |
phase trial | 11 |
lung damage | 11 |
alveolar epithelial | 11 |
treated patients | 11 |
high incidence | 11 |
th percentile | 11 |
human cd | 11 |
el primer | 11 |
like covs | 11 |
respiratoria aguda | 11 |
also identified | 11 |
host receptor | 11 |
affected patients | 11 |
may present | 11 |
vitro studies | 11 |
pacientes tratados | 11 |
en wuhan | 11 |
two groups | 11 |
st century | 11 |
potential intermediate | 11 |
efectos adversos | 11 |
ejection fraction | 11 |
better understanding | 11 |
angiotensinconverting enzyme | 11 |
therapeutic drugs | 11 |
related coronaviruses | 11 |
analysis clinical | 11 |
un grupo | 11 |
comparative therapeutic | 11 |
estudio retrospectivo | 11 |
digital governance | 11 |
studies suggested | 11 |
different countries | 11 |
anal swabs | 11 |
rna synthesis | 11 |
mitigation measures | 11 |
corel corporation | 11 |
psychiatric hospitals | 11 |
respiratorio agudo | 11 |
china epidemiological | 11 |
illness onset | 11 |
infected individual | 11 |
oral route | 11 |
situation reports | 11 |
activation syndrome | 11 |
antiviral action | 11 |
interquartile range | 11 |
hospital staff | 11 |
peer review | 11 |
los medicamentos | 11 |
enfermedad severa | 11 |
also observed | 11 |
disease covid | 11 |
rhesus monkeys | 11 |
cuidados paliativos | 11 |
humoral immune | 11 |
inflammatory mediators | 11 |
phase iii | 11 |
five patients | 11 |
young people | 11 |
rapid development | 11 |
human angiotensin | 11 |
endothelial cells | 11 |
key role | 11 |
international health | 11 |
coronavirus study | 11 |
randomized trial | 11 |
quantitative rt | 11 |
como un | 11 |
causing severe | 11 |
higher level | 11 |
todas las | 11 |
competing interests | 11 |
official publication | 11 |
ventilated patients | 11 |
del plasma | 11 |
coronaviruses sars | 11 |
significantly lower | 11 |
gene expression | 11 |
among others | 11 |
emerging human | 11 |
patients died | 11 |
clinical predictors | 11 |
canine coronavirus | 11 |
recent report | 11 |
reduced mortality | 11 |
diagnose novel | 11 |
mental disorders | 11 |
necrosis factor | 11 |
pooled prevalence | 11 |
acute hypoxemic | 11 |
por un | 11 |
serum antibody | 11 |
recent reports | 11 |
spread via | 11 |
among healthcare | 11 |
pediatric covid | 11 |
therapeutic strategy | 11 |
antibody tests | 11 |
randomized trials | 11 |
northern italy | 11 |
reservoir host | 11 |
potential antiviral | 11 |
los siguientes | 11 |
east asia | 11 |
existe una | 11 |
primary care | 11 |
cellular immune | 11 |
poor outcomes | 11 |
three patients | 11 |
high levels | 11 |
infect dis | 11 |
nursing homes | 11 |
los hallazgos | 11 |
health approach | 11 |
ser una | 11 |
patient care | 11 |
el nivel | 11 |
human cell | 11 |
coronavirus vaccine | 11 |
high prevalence | 11 |
small molecule | 11 |
transmission routes | 11 |
among hospitalized | 11 |
stress disorder | 11 |
del equipo | 11 |
specific therapeutic | 11 |
among nurses | 11 |
vaccine candidates | 11 |
male patients | 11 |
palm civet | 11 |
cardiovascular diseases | 11 |
deaths worldwide | 11 |
aumento en | 11 |
nk cells | 11 |
liver enzymes | 11 |
new insights | 11 |
surge capacity | 11 |
disease clinical | 11 |
informed consent | 11 |
el virus | 11 |
dromedary camels | 11 |
sample collection | 10 |
hipoxemia refractaria | 10 |
spread worldwide | 10 |
old man | 10 |
tidal volume | 10 |
general public | 10 |
real time | 10 |
community spread | 10 |
greater risk | 10 |
lung lesions | 10 |
surgical mask | 10 |
rapidly evolving | 10 |
inhaled nitric | 10 |
study published | 10 |
may contribute | 10 |
cesarean section | 10 |
case isolation | 10 |
el procedimiento | 10 |
even death | 10 |
first days | 10 |
bei erwachsenen | 10 |
membrane protein | 10 |
una mayor | 10 |
become infected | 10 |
vaccine candidate | 10 |
nosocomial transmission | 10 |
ncov epidemic | 10 |
natural history | 10 |
influenza viruses | 10 |
blood cells | 10 |
pathogenic human | 10 |
symptomatic patient | 10 |
small number | 10 |
critical disease | 10 |
practice guideline | 10 |
lung tissues | 10 |
se encuentran | 10 |
supportive therapy | 10 |
lung function | 10 |
wet market | 10 |
previously reported | 10 |
prevent transmission | 10 |
recomienda considerar | 10 |
patients will | 10 |
among people | 10 |
symptomatic rates | 10 |
imported cases | 10 |
pulmonary vascular | 10 |
viral pathogens | 10 |
pharyngeal swabs | 10 |
extracorporeal life | 10 |
retrospective analysis | 10 |
rapid review | 10 |
related stress | 10 |
crisis management | 10 |
statistical analysis | 10 |
en tiempos | 10 |
spread across | 10 |
also considered | 10 |
acute myocarditis | 10 |
index patient | 10 |
tomar decisiones | 10 |
intestinal organoids | 10 |
epidemic curve | 10 |
better understand | 10 |
evitar el | 10 |
infectious sars | 10 |
epidemiological parameters | 10 |
approximately days | 10 |
virus particles | 10 |
high rate | 10 |
del inicio | 10 |
hydroxychloroquine sulfate | 10 |
asian countries | 10 |
highest number | 10 |
clinical use | 10 |
mortality risk | 10 |
rapidly spread | 10 |
previous study | 10 |
cell counts | 10 |
elevation myocardial | 10 |
acid amplification | 10 |
sars pandemic | 10 |
will continue | 10 |
therapeutic option | 10 |
patients develop | 10 |
mouse anti | 10 |
big data | 10 |
skeletal muscle | 10 |
muscle injury | 10 |
organ systems | 10 |
percutaneous coronary | 10 |
paving pattern | 10 |
saliva samples | 10 |
large amounts | 10 |
stainless steel | 10 |
fatal outcomes | 10 |
several reports | 10 |
host ace | 10 |
debe considerar | 10 |
becomes available | 10 |
regression analysis | 10 |
risk patients | 10 |
performed using | 10 |
herbal medicines | 10 |
pathogenic coronavirus | 10 |
liver function | 10 |
randomised controlled | 10 |
existe evidencia | 10 |
small sample | 10 |
las horas | 10 |
patients recovered | 10 |
incidence rate | 10 |
effective antiviral | 10 |
pcr para | 10 |
radiographic findings | 10 |
symptoms include | 10 |
storm syndromes | 10 |
well known | 10 |
thrombotic complications | 10 |
commons attribution | 10 |
old age | 10 |
bilateral patchy | 10 |
systemic corticosteroids | 10 |
en estos | 10 |
chest radiography | 10 |
zoonotic origin | 10 |
realizar el | 10 |
bilateral pneumonia | 10 |
coronary syndrome | 10 |
use authorization | 10 |
estancia hospitalaria | 10 |
transmission patterns | 10 |
ventilatory support | 10 |
potential evidence | 10 |
pandemic response | 10 |
health response | 10 |
effective treatments | 10 |
low risk | 10 |
erythrocyte sedimentation | 10 |
viral titers | 10 |
type diabetes | 10 |
cardiac dysfunction | 10 |
interstitial pneumonia | 10 |
two weeks | 10 |
igm antibodies | 10 |
contact history | 10 |
puede considerar | 10 |
hospital death | 10 |
en esta | 10 |
case study | 10 |
virtual screening | 10 |
alveolar cells | 10 |
effective concentration | 10 |
rural areas | 10 |
early humoral | 10 |
perceived health | 10 |
todo el | 10 |
pneumonia emergency | 10 |
se pueden | 10 |
angiotensin receptor | 10 |
kabasuraneer choornam | 10 |
multiple sclerosis | 10 |
en algunos | 10 |
induced acute | 10 |
terminal domain | 10 |
patient samples | 10 |
elderly people | 10 |
retrospective observational | 10 |
phase ii | 10 |
social distance | 10 |
blood samples | 10 |
common clinical | 10 |
recomienda utilizar | 10 |
increased levels | 10 |
current knowledge | 10 |
vital role | 10 |
penn state | 10 |
age distribution | 10 |
moderate coronavirus | 10 |
pediatric sars | 10 |
los epp | 10 |
healthcare providers | 10 |
also present | 10 |
regression model | 10 |
cited publication | 10 |
inanimate surfaces | 10 |
pressure ventilation | 10 |
salud mental | 10 |
times higher | 10 |
contaminated surfaces | 10 |
western medicine | 10 |
refractory hypoxemia | 10 |
air travel | 10 |
por los | 10 |
underlying cardiovascular | 10 |
hand washing | 10 |
assisted reproductive | 10 |
stimulating factor | 10 |
first patients | 10 |
eventos adversos | 10 |
rna polymerases | 10 |
circulatory support | 10 |
inflammatory effects | 10 |
remain viable | 10 |
relacionadas con | 10 |
infections among | 10 |
cov spike | 10 |
bacterial infections | 10 |
human excreta | 10 |
oropharyngeal swabs | 10 |
task force | 10 |
negative rt | 10 |
consider cytokine | 10 |
recent insights | 10 |
medical observation | 10 |
union hospital | 10 |
health organisation | 10 |
profiling early | 10 |
mortality among | 10 |
lower mortality | 10 |
treatment program | 10 |
chronic respiratory | 10 |
contra el | 10 |
largest number | 10 |
current covid | 10 |
inhibitors targeting | 10 |
commercially available | 10 |
positive airway | 10 |
wuhan epidemiological | 9 |
para determinar | 9 |
tract symptoms | 9 |
species severe | 9 |
palm civets | 9 |
well established | 9 |
hazard ratio | 9 |
cell epitopes | 9 |
body mass | 9 |
mathematical models | 9 |
epidemiological history | 9 |
cardiovascular implications | 9 |
antiviral treatments | 9 |
psychosocial interventions | 9 |
another coronavirus | 9 |
nausea vomiting | 9 |
private sector | 9 |
nucleotide identity | 9 |
coronavirus detection | 9 |
air bronchograms | 9 |
lower levels | 9 |
local health | 9 |
also demonstrated | 9 |
found throughout | 9 |
masked palm | 9 |
aerosol transmission | 9 |
severe lung | 9 |
acid test | 9 |
expert group | 9 |
viral spike | 9 |
sobre los | 9 |
jak inhibitors | 9 |
million cases | 9 |
diseases society | 9 |
significant number | 9 |
storm syndrome | 9 |
pandemic situation | 9 |
first two | 9 |
ec values | 9 |
el marco | 9 |
temporal profiles | 9 |
pcr assay | 9 |
potential domestic | 9 |
patients outside | 9 |
including hypertension | 9 |
cov ratg | 9 |
surgical face | 9 |
animal market | 9 |
nasopharyngeal swabs | 9 |
initial stage | 9 |
animal markets | 9 |
spread globally | 9 |
google scholar | 9 |
breast cancer | 9 |
review aims | 9 |
wet markets | 9 |
european countries | 9 |
mathematical model | 9 |
systemic inflammation | 9 |
serological testing | 9 |
traumatic stress | 9 |
healthcare system | 9 |
like disease | 9 |
aged years | 9 |
supportive treatment | 9 |
lower lobe | 9 |
inhibitory activity | 9 |
potential vaccine | 9 |
previous sars | 9 |
like covid | 9 |
seguridad del | 9 |
included fever | 9 |
cardiac involvement | 9 |
treatment effects | 9 |
genome composition | 9 |
posterior oropharyngeal | 9 |
every day | 9 |
brain barrier | 9 |
samples collected | 9 |
patient population | 9 |
acute phase | 9 |
se deben | 9 |
study early | 9 |
major outbreak | 9 |
del compromiso | 9 |
ii receptor | 9 |
proinflammatory cytokines | 9 |
therapeutic potential | 9 |
average age | 9 |
systemic review | 9 |
clinical severity | 9 |
symptomatic infections | 9 |
por encima | 9 |
moderate forms | 9 |
attack rate | 9 |
social isolation | 9 |
replication cycle | 9 |
support corticosteroid | 9 |
persistent fecal | 9 |
third trimester | 9 |
relatively small | 9 |
heart rate | 9 |
en medicina | 9 |
research team | 9 |
disease modeling | 9 |
severe clinical | 9 |
household transmission | 9 |
daily cases | 9 |
reproductive treatments | 9 |
dysfunction syndrome | 9 |
care personnel | 9 |
spike receptor | 9 |
coronary heart | 9 |
swine flu | 9 |
presenting characteristics | 9 |
mouth twice | 9 |
combined chinese | 9 |
acute cerebrovascular | 9 |
cancer diagnosis | 9 |
medical personnel | 9 |
pcr tests | 9 |
viral polymerase | 9 |
table shows | 9 |
systematic reviews | 9 |
amniotic fluid | 9 |
patients clinical | 9 |
clinical guidance | 9 |
oxygen supply | 9 |
coronary angiography | 9 |
ards patients | 9 |
oropharyngeal swab | 9 |
cruise ships | 9 |
hyaline membrane | 9 |
tract samples | 9 |
para establecer | 9 |
generation sequencing | 9 |
working group | 9 |
como las | 9 |
several cases | 9 |
digital pcr | 9 |
surface glycoprotein | 9 |
sars cases | 9 |
comparative study | 9 |
much lower | 9 |
tumor necrosis | 9 |
newly identified | 9 |
un tratamiento | 9 |
th march | 9 |
visiting wuhan | 9 |
dentro del | 9 |
secondary bacterial | 9 |
antiviral gs | 9 |
two decades | 9 |
liver disease | 9 |
potential therapy | 9 |
del recurso | 9 |
combat covid | 9 |
genomic rna | 9 |
humoral immunity | 9 |
dos veces | 9 |
supplemental oxygen | 9 |
infected children | 9 |
high rates | 9 |
tertiary care | 9 |
virus isolation | 9 |
respiratory tracts | 9 |
cell count | 9 |
personal sanitario | 9 |
resonance imaging | 9 |
patients experienced | 9 |
based detection | 9 |
proximal origin | 9 |
medical resources | 9 |
preliminary data | 9 |
million mark | 9 |
pulmonary arterial | 9 |
prospective observational | 9 |
plasma transfusion | 9 |
time period | 9 |
pandemic period | 9 |
data analysis | 9 |
response epidemiology | 9 |
evaluar el | 9 |
among health | 9 |
human cases | 9 |
aerosol generating | 9 |
highest risk | 9 |
host range | 9 |
open reading | 9 |
including patients | 9 |
unknown cause | 9 |
respiratory coronavirus | 9 |
immunological studies | 9 |
con sars | 9 |
rapid increase | 9 |
cases worldwide | 9 |
se considera | 9 |
prevent infection | 9 |
troponin i | 9 |
ncov lung | 9 |
pathological features | 9 |
medicine treatment | 9 |
potential risk | 9 |
late december | 9 |
study revealed | 9 |
prone ventilation | 9 |
receiving chemotherapy | 9 |
lymphocyte ratio | 9 |
ic del | 9 |
community containment | 9 |
del estudio | 9 |
people worldwide | 9 |
study involving | 9 |
estudios han | 9 |
bilateral lung | 9 |
el proceso | 9 |
pacientes sin | 9 |
fight covid | 9 |
el plasma | 9 |
multicentre trial | 9 |
bronchitis virus | 9 |
five cases | 9 |
viral etiology | 9 |
genetic sequencing | 9 |
antigen receptor | 9 |
mortalidad en | 9 |
vaccine targets | 9 |
oropharyngeal saliva | 9 |
short time | 9 |
influenza infection | 9 |
candidate vaccines | 9 |
closely monitored | 9 |
coronary intervention | 9 |
current scenario | 9 |
health status | 9 |
pacientes adultos | 9 |
soporte ventilatorio | 9 |
extreme measures | 9 |
lombardy region | 9 |
highly effective | 9 |
common among | 9 |
del sars | 9 |
el retiro | 9 |
clinical deterioration | 9 |
enzyme inhibitors | 9 |
exposure history | 9 |
higher number | 9 |
contact transmission | 9 |
face shield | 9 |
pcr assays | 9 |
laboratory confirmed | 9 |
take place | 9 |
ill icu | 9 |
novel viruses | 9 |
moderate disease | 9 |
scoping review | 9 |
traditional medicines | 9 |
lung ultrasound | 9 |
elevated serum | 9 |
chimeric antigen | 9 |
critical role | 9 |
sedimentation rate | 9 |
en todos | 9 |
common symptom | 9 |
severe infections | 8 |
previous coronavirus | 8 |
secondary infections | 8 |
los elementos | 8 |
mask production | 8 |
social contacts | 8 |
los participantes | 8 |
neuraminidase inhibitors | 8 |
people will | 8 |
von sars | 8 |
para lograr | 8 |
adaptive immunity | 8 |
test positive | 8 |
maximal effective | 8 |
may show | 8 |
published data | 8 |
posttraumatic stress | 8 |
likely due | 8 |
highly conserved | 8 |
commonly reported | 8 |
therapeutic agent | 8 |
additional file | 8 |
natriuretic peptide | 8 |
diagnosis included | 8 |
beta coronavirus | 8 |
symptomatic treatment | 8 |
live attenuated | 8 |
se encontraban | 8 |
measures taken | 8 |
symptomatic individuals | 8 |
con falla | 8 |
vivo studies | 8 |
flush toilets | 8 |
several clinical | 8 |
lupus erythematosus | 8 |
infection transmission | 8 |
long time | 8 |
ivermectin inhibits | 8 |
stool specimens | 8 |
antibody titer | 8 |
nosocomial spread | 8 |
asymptomatic infected | 8 |
positive mothers | 8 |
interspecies transmission | 8 |
clinical recovery | 8 |
become available | 8 |
systemic inflammatory | 8 |
sense single | 8 |
available evidence | 8 |
mitigation strategies | 8 |
vero cells | 8 |
mild pneumonia | 8 |
diagnostic tools | 8 |
four cases | 8 |
previous outbreaks | 8 |
lunar new | 8 |
systemic hyperinflammation | 8 |
nasal congestion | 8 |
convaleciente en | 8 |
influenza pneumonia | 8 |
accurate diagnosis | 8 |
serum il | 8 |
underlying conditions | 8 |
individual patient | 8 |
total deaths | 8 |
th edition | 8 |
genetic sequences | 8 |
colleagues reported | 8 |
coping strategies | 8 |
related deaths | 8 |
pacientes se | 8 |
cases per | 8 |
worldwide pandemic | 8 |
infected mother | 8 |
hypertensive patients | 8 |
hiv protease | 8 |
failure assessment | 8 |
command center | 8 |
initial stages | 8 |
las unidades | 8 |
ribonucleic acid | 8 |
hopkins university | 8 |
spanish influenza | 8 |
possible vertical | 8 |
clinical status | 8 |
entre otros | 8 |
disease pandemic | 8 |
acquired immunity | 8 |
symptoms including | 8 |
symptoms like | 8 |
several days | 8 |
will require | 8 |
el plan | 8 |
wuhan outbreak | 8 |
viral genomes | 8 |
chinese journal | 8 |
data showed | 8 |
nervioso central | 8 |
bmj global | 8 |
daily new | 8 |
common ancestor | 8 |
se realiza | 8 |
patients include | 8 |
acute necrotizing | 8 |
fio mmhg | 8 |
may affect | 8 |
infection covid | 8 |
international public | 8 |
airway management | 8 |
acid sequences | 8 |
tissue damage | 8 |
cohort studies | 8 |
reports suggest | 8 |
todo paciente | 8 |
patients whose | 8 |
triple combination | 8 |
studies suggest | 8 |
drug ivermectin | 8 |
en situaciones | 8 |
genomic sequences | 8 |
digital lamp | 8 |
initial symptoms | 8 |
homology modeling | 8 |
taken together | 8 |
por su | 8 |
spread among | 8 |
specific drugs | 8 |
el efecto | 8 |
therapeutic effect | 8 |
diagnostic testing | 8 |
las decisiones | 8 |
showed bilateral | 8 |
nursing facility | 8 |
eye protection | 8 |
th cases | 8 |
una enfermedad | 8 |
suspected patients | 8 |
new england | 8 |
complement activation | 8 |
treating patients | 8 |
one case | 8 |
toxic derivative | 8 |
secondary cases | 8 |
linked immunosorbent | 8 |
pulmonary pathology | 8 |
wild animal | 8 |
pneumonia monitored | 8 |
american thoracic | 8 |
respiratory secretions | 8 |
liver transplant | 8 |
und die | 8 |
con base | 8 |
long term | 8 |
sistema nervioso | 8 |
primeras horas | 8 |
recovery rate | 8 |
care facility | 8 |
disease will | 8 |
acid substitutions | 8 |
stay home | 8 |
clinical spectrum | 8 |
patients might | 8 |
basada en | 8 |
milder symptoms | 8 |
chinese population | 8 |
china seafood | 8 |
en salas | 8 |
ongoing pandemic | 8 |
medical sciences | 8 |
reduce transmission | 8 |
el desarrollo | 8 |
es posible | 8 |
neonatal outcomes | 8 |
human cov | 8 |
neonatal covid | 8 |
human population | 8 |
high expression | 8 |
mild respiratory | 8 |
las manifestaciones | 8 |
novel wuhan | 8 |
therapeutic target | 8 |
neuropsychiatric manifestations | 8 |
en falla | 8 |
nasal cavity | 8 |
virus load | 8 |
iii clinical | 8 |
epidemic prevention | 8 |
mass index | 8 |
extrapulmonary manifestations | 8 |
patients covid | 8 |
soc group | 8 |
con alta | 8 |
blood urea | 8 |
una sensibilidad | 8 |
severe conditions | 8 |
cellular immunity | 8 |
also showed | 8 |
without cancer | 8 |
riesgo para | 8 |
developed severe | 8 |
un modelo | 8 |
cell therapy | 8 |
disease may | 8 |
cuales se | 8 |
highly pathogenic | 8 |
adenovirus type | 8 |
neck surgery | 8 |
week later | 8 |
cardiovascular comorbidities | 8 |
caused tertiary | 8 |
monocytes macrophages | 8 |
fold higher | 8 |
endothelial cell | 8 |
falsos negativos | 8 |
base en | 8 |
approved drugs | 8 |
escala news | 8 |
recent developments | 8 |
igm antibody | 8 |
special attention | 8 |
diabetic patients | 8 |
ha reportado | 8 |
right lower | 8 |
liver damage | 8 |
superspreading events | 8 |
peripheral nervous | 8 |
old female | 8 |
las pruebas | 8 |
healthy individuals | 8 |
approved drug | 8 |
el equipo | 8 |
cases will | 8 |
autoimmune diseases | 8 |
ill patient | 8 |
reduce viral | 8 |
rdrp hel | 8 |
los protocolos | 8 |
pay attention | 8 |
new infections | 8 |
two bat | 8 |
los diferentes | 8 |
health centers | 8 |
longer period | 8 |
tertiary transmission | 8 |
national natural | 8 |
since december | 8 |
potential route | 8 |
biocidal agents | 8 |
coronavirus envelope | 8 |
significant impact | 8 |
epithelial cell | 8 |
natural host | 8 |
significantly reduce | 8 |
system manifestations | 8 |
endothelial dysfunction | 8 |
remains unknown | 8 |
molecular diagnosis | 8 |
vulnerable populations | 8 |
evidence shows | 8 |
developing vaccines | 8 |
medical community | 8 |
air quality | 8 |
underlying comorbidities | 8 |
potential anti | 8 |
pediatric cases | 8 |
uso en | 8 |
unfractionated heparin | 8 |
human infections | 8 |
antithrombotic therapy | 8 |
four genera | 8 |
pandemia por | 8 |
se presenta | 8 |
viral testing | 8 |
personal protection | 8 |
chinese authorities | 8 |
first wave | 8 |
china national | 8 |
soporte respiratorio | 8 |
coronavirus outbreaks | 8 |
exploratory meta | 8 |
tocilizumab treatment | 8 |
identified coronavirus | 8 |
infection diagnosis | 8 |
collective strategies | 8 |
elevated troponin | 8 |
convalescent sera | 8 |
also possible | 8 |
antiviral remdesivir | 8 |
cases may | 8 |
overall mortality | 8 |
gi symptoms | 8 |
movement restrictions | 8 |
chinese society | 8 |
cord mesenchymal | 8 |
en sdra | 8 |
median duration | 8 |
significant increase | 8 |
aquellos pacientes | 8 |
cytokines including | 8 |
sao fio | 8 |
nasal swabs | 8 |
laboratory confirmation | 8 |
entre otras | 8 |
disease spread | 8 |
front line | 8 |
como en | 8 |
different animal | 8 |
large proportion | 8 |
false negative | 8 |
successfully isolated | 8 |
viruses including | 8 |
mers patients | 8 |
se cuenta | 8 |
supplementary material | 8 |
del procedimiento | 8 |
transcriptase polymerase | 8 |
los cambios | 8 |
associated coagulopathy | 8 |
una herramienta | 8 |
flow rates | 8 |
transmission among | 8 |
health conditions | 8 |
coronavirus entry | 8 |
como se | 8 |
neurologic symptoms | 8 |
prevention measures | 8 |
peripheral cannulation | 8 |
study design | 8 |
drug interactions | 8 |
care professionals | 8 |
following criteria | 8 |
careful consideration | 8 |
clinical application | 8 |
chinese experience | 8 |
mg daily | 8 |
pacientes infectados | 8 |
mouse models | 8 |
treat patients | 8 |
functional exhaustion | 8 |
demographic characteristics | 8 |
two consecutive | 8 |
hiv aids | 8 |
un total | 7 |
authors concluded | 7 |
improved clinical | 7 |
induced ards | 7 |
fetal distress | 7 |
may prove | 7 |
studies show | 7 |
nurses working | 7 |
patients younger | 7 |
prospective study | 7 |
en lo | 7 |
infection may | 7 |
psychosocial factors | 7 |
live virus | 7 |
clinical condition | 7 |
son los | 7 |
wuhan china | 7 |
virtual databases | 7 |
infections caused | 7 |
polymerase amplification | 7 |
without diarrhea | 7 |
kenyan population | 7 |
genetic diversity | 7 |
lung cells | 7 |
cov may | 7 |
wuhan covid | 7 |
international travel | 7 |
independent risk | 7 |
educational institutions | 7 |
strand rna | 7 |
chloroquine diphosphate | 7 |
health threat | 7 |
el caso | 7 |
transmission within | 7 |
vitro data | 7 |
also important | 7 |
tests based | 7 |
cox regression | 7 |
positive end | 7 |
el remdesivir | 7 |
en mayo | 7 |
shed light | 7 |
new drug | 7 |
adjunctive therapy | 7 |
renal en | 7 |
travel restrictions | 7 |
antiviral therapies | 7 |
first detected | 7 |
currently underway | 7 |
volumen corriente | 7 |
bioinformatics analysis | 7 |
ml kg | 7 |
data collection | 7 |
exponential growth | 7 |
clinical conditions | 7 |
zhejiang province | 7 |
con otros | 7 |
urea nitrogen | 7 |
pandemic virus | 7 |
cell infiltration | 7 |
las siguientes | 7 |
cannula approach | 7 |
risk groups | 7 |
catheterization laboratory | 7 |
bovine coronavirus | 7 |
molecular target | 7 |
virus targeting | 7 |
spread around | 7 |
el hospital | 7 |
enteral nutrition | 7 |
immune activation | 7 |
dengue virus | 7 |
direct myocardial | 7 |
los biomarcadores | 7 |
acute viral | 7 |
intravascular coagulopathy | 7 |
formal analysis | 7 |
oxidative stress | 7 |
cytopathic effect | 7 |
publicly available | 7 |
plasma exchange | 7 |
asociados con | 7 |
commonly found | 7 |
series clinical | 7 |
animal hosts | 7 |
multicenter prospective | 7 |
icu beds | 7 |
bloqueo neuromuscular | 7 |
potential drugs | 7 |
loading dose | 7 |
science foundation | 7 |
acute heart | 7 |
el seguimiento | 7 |
el coronavirus | 7 |
receiving combined | 7 |
suspected human | 7 |
higher affinity | 7 |
repurposed drugs | 7 |
targeted therapies | 7 |
continuous variables | 7 |
determine whether | 7 |
also play | 7 |
pandemic disease | 7 |
symptoms among | 7 |
inflammatory properties | 7 |
like virus | 7 |
pediatric population | 7 |
early outbreak | 7 |
routine use | 7 |
positive test | 7 |
una unidad | 7 |
underlying disease | 7 |
crazy paving | 7 |
para definir | 7 |
principalmente en | 7 |